ClinicalTrials.gg
Not yet recruitingNCT07662304Updated Jun 23, 2026

Effect of Continuous Supraglottic Oxygen Insufflation Via Video Laryngoscope Blade on Apneic Oxygenation During Tracheal Intubation Under General Anesthesia

An interventional study of control group (Group C) and The continuous laryngeal oxygen supply group (Group B) in Apneic Oxygenation, sponsored by Affiliated Hospital of Jiaxing University. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by Affiliated Hospital of Jiaxing University · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study is a prospective, randomized controlled clinical trial aimed at investigating the efficacy and safety of a novel oxygenating video laryngoscope blade during apneic oxygenation for intubation under general anesthesia. Hypoxemia is prone to occur during anesthesia induction, which can lead to severe complications. Apneic oxygenation is an important method to prolong the safe apnea time, but existing oxygen delivery modalities have limitations in applicability. Although the laryngeal oxygen delivery approach combined with video laryngoscopy has theoretical advantages, clinical evidence is insufficient. Therefore, this study was conducted.

02

Conditions studied

  • Apneic Oxygenation

Keywords

  • video laryngoscope
03

In context

Lead sponsor

Affiliated Hospital of Jiaxing University is the lead sponsor of 17 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged between 18 and 75 years, with I to III, and scheduled for surgery with general anaesthesia and orotracheal intubation

Exclusion criteria

Exclusion Criteria:

  • cardiac disease (ischaemic heart disease, heart failure [ ≥2 ],current arrhythmias, pulmonary hypertension)
  • severe asthma, moderate to severe
  • pregnancy
  • baseline oxygen saturation \<95%
  • not capable of understanding study information and signing a written consent
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Active comparator
    control group (Group C)

    Before surgery, all participants received a radial arterial line. Participants were then placed supine, in a 10 degrees reverse Trendelenburg position. Preoxygenation was then performed using atight fitting face mask and having Tracheal intubation was thereafter performed using a video laryngoscopewhen the anaesthetist assessed the conditions as appropriate in the control group (Group C).The correct placement of the tracheal tube was confirmed visually by the anaesthetist in charge and a member of the study team. The tracheal tube was secured, and the participant was left apnoeic with the tracheal tube open to the atmosphere until the peripheral oxygen saturation declined to 93% or apnoea is sustained for 5 minutes.

    Procedure: control group (Group C)

  • Experimental
    The continuous laryngeal oxygen supply group (Group B)

    The continuous laryngeal oxygen supply group (Group B) used the same preoxygenation and anesthesia induction methods as the control group. When intubation conditions were assessed to be met, laryngoscopy was performed to evaluate the airway. If the laryngoscopic view was Cormack and Lehane grade 3 or grade 4, the subject was excluded from the study and tracheal intubation was performed. Otherwise, continuous laryngeal oxygen supply was initiated through a modified disposable video laryngoscope blade, which has an internal lumen. The distal end of the blade is connected to an oxygen delivery tube, and the other end of the oxygen delivery tube is connected to a flowmeter, with an oxygen flow rate of 10 L/min to maintain a continuous oxygen supply to the larynx. During apnoea, anaesthesia was maintained with intermittent boluses of propofol and, if necessary, either infusion of remifentanil. Upon reaching an SpO2 of 93% or apnoea is sustained for 5 minutes, tracheal intubation and mechan

    Device: The continuous laryngeal oxygen supply group (Group B)

Interventions

  • Procedurecontrol group (Group C)

    Before surgery, all participants received a radial arterial line. At arrival to the operating theatre, ECG, invasive arterial blood pressure, pulse oximetry, and train-of-four monitoring were applied. An i.v. line was secured, and a standard infusion of electrolyte solution was started. Participants were then placed supine, in a 10 degrees reverse Trendelenburg position. Preoxygenation was then perform using atight fitting face mask and having each subject breathe 100% O2 at 15 L/min.Tracheal intubation was thereafter performed using a video laryngoscope when the anaesthetist assessed the conditions as appropriate in the control group (Group C).The correct placement of the tracheal tube was confirmed visually by the anaesthetist in charge and a member of the study team. The tracheal tube was secured, and the participant was left apnoeic with the tracheal tube open to the atmosphere until the peripheral oxygen saturation declined to 93% or apnoea is sustained for 5 minutes.

  • DeviceThe continuous laryngeal oxygen supply group (Group B)

    The continuous laryngeal oxygen supply group (Group B) used the same preoxygenation and anesthesia induction methods as the control group. When intubation conditions were assessed to be met, laryngoscopy was performed to evaluate the airway. If the laryngoscopic view was Cormack and Lehane grade 3 or grade 4, the subject was excluded from the study and tracheal intubation was performed. Otherwise, continuous laryngeal oxygen supply was initiated through a modified disposable video laryngoscope blade, which has an internal lumen. The distal end of the blade is connected to an oxygen delivery tube, and the other end of the oxygen delivery tube is connected to a flowmeter, with an oxygen flow rate of 10 L/min to maintain a continuous oxygen supply to the larynx. Upon reaching an SpO2 of 93% or apnoea is sustained for 5 minutes, tracheal intubation and mechanical ventilation was commenced, and the protocol was terminated.

06

What researchers measure

Primary outcomes

  1. arterial partial pressure of oxygen (PaO2) at 3 min

    arterial partial pressure of oxygen (PaO2) at 3 min when intubation criteria are met

    Time frame: 3 minutes after intubation

Secondary outcomes

  1. PaO2 at before preoxygenation

    Time frame: Baseline (before preoxygenation)

  2. PaO2 at 1 minutes when intubation criteria are met

    Time frame: 1 minute after intubation

  3. PaO2 at 2 minute when intubation criteria are met

    Time frame: 2 minute after intubation

  4. PaO2 at 5 minutes when intubation criteria are met

    Time frame: 5 minute after intubation

  5. PaCO2 changes during apnoea

    Time frame: up to 24 hours (during apnoea)

  6. all complicatios at 24 hours postoperatively.

    Time frame: at 24 hours postoperatively

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Jun 2026, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2026
First posted
Jun 23, 2026
StartEst.
Jun 22, 2026
Primary completionEst.
Jun 22, 2026
CompletionEst.
Jun 22, 2029
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07662304
Lead sponsor
Affiliated Hospital of Jiaxing University
Collaborators
The Second Affiliated Hospital of Jiaxing University
Responsible party
Qing-he Zhou (PHD, The Second Affiliated Hospital of Jiaxing University) — Principal investigator
First posted
Jun 23, 2026
Start date
Jun 22, 2026 (estimated)
Primary completion
Jun 22, 2026 (estimated)
Completion
Jun 22, 2029 (estimated)
Last update
Jun 23, 2026

Study contacts

Daqing Pei
Contact
ph287594683@163.com
+8615068353937

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion